Quarterly ResultMay 1, 2026, 05:02 PM
Tonix Pharma Q1 Revenue $6.9M; Net Loss $40.8M
AI Summary
Tonix Pharmaceuticals reported preliminary financial results for Q1 2026, with net revenue from marketed products significantly increasing to approximately $6.9 million, up from $2.4 million in Q1 2025. This growth was driven by the launch of TONMYA® and continued sales of Zembrace® SymTouch® and Tosymra®. However, the company's net loss widened to approximately $40.8 million, compared to $16.8 million in the prior year, and net cash used in operating activities also increased substantially. The company expects its cash resources, including $17.4 million from recent equity offerings, to fund operations into Q2 2027.
Key Highlights
- Q1 2026 net revenue from marketed products was approximately $6.9 million, up from $2.4 million in Q1 2025.
- Q1 2026 net loss was approximately $40.8 million, compared to $16.8 million in Q1 2025.
- Cash and cash equivalents totaled approximately $185.5 million as of March 31, 2026.
- Net cash used in operating activities for Q1 2026 was approximately $40.2 million, up from $16.6 million in Q1 2025.
- TONMYA® generated approximately $3.7 million in net revenue for Q1 2026, following its November 2025 launch.
- Zembrace® SymTouch® and Tosymra® contributed approximately $3.2 million in net revenue for Q1 2026.
- The company expects to fund operations into Q2 2027 with current cash and $17.4 million from equity offerings.